The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index; 4 of the 10 sources its claims cite were checked for support.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Open accessAbstract
BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma. METHODS: CAR-positive (CAR+) T cells. The primary end point was an overall response (partial response or better); a key secondary end point was a complete response or better (comprising complete and stringent complete responses). RESULTS: nucleated cells) was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better. The median progression-free survival was 8.8 months (95% confidence interval, 5.6 to 11.6). Common toxic effects among the 128 treated patients included neutropenia in 117 patients (91%), anemia in 89 (70%), and thrombocytopenia in 81 (63%). Cytokine release syndrome was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher. Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%); no neurotoxic effects higher than grade 3 occurred. Cellular kinetic analysis confirmed CAR+ T cells in 29 of 49 patients (59%) at 6 months and 4 of 11 patients (36%) at 12 months after infusion. CONCLUSIONS: Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost all patients had grade 3 or 4 toxic effects, most commonly hematologic toxic effects and cytokine release syndrome. (Funded by bluebird bio and Celgene, a Bristol-Myers Squibb company; KarMMa ClinicalTrials.gov number, NCT03361748.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 of 10 cited sources checked · 2 supported · 0 flagged · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“The B-cell maturation antigen (BCMA)-directed CAR T cell idecabtagene vicleucel (ide-cel, also called bb2121) showed promising efficacy in a phase 1 study involving patients with relapsed or refractory myeloma.11”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > D
What the sources say
- Supportedcites [11] 11. Raje N, Berdeja J, Lin Y, et al. Anti- BCMA CAR T-cell therapy bb2121 in re- lapsed or refractory multiple myeloma. N Engl J Med 2019; 380: 1726-37. source
The Methods identify bb2121 as an anti-BCMA CAR T-cell therapy studied in a phase 1 trial involving patients with relapsed or refractory multiple myeloma. The Discussion reports an 85% clinical response rate, supporting the characterization of its efficacy as promising. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These efficacy results compare favorably with results in similarly heavily pretreated patients with relapsed or refractory myeloma treated with two recently approved regimens, selinexor plus dexamethasone and belantamab mafodotin (median progression-free survival, 3.7 months and 2.9 months, respectively).5,17”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Supportedcites [5] 5. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019; 381: 727-38. source
The Methods and Discussion describe patients with triple-class refractory myeloma who were heavily pretreated, with a median of seven previous regimens. The Efficacy section reports median progression-free survival of 3.7 months with selinexor plus dexamethasone. This citation supports the selinexor result; the separate belantamab result is not attributed to this paper. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [17] 17. Lonial S, Lee HC, Badros A, et al. Belan- tamab mafodotin for relapsed or refracto- ry multiple myeloma (DREAMM-2): a two- arm, randomised, open-label, phase 2 study. Lancet Oncol 2020; 21: 207-21. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: Cross-trial comparisons of progression-free survival between the KarMMa study and trials of selinexor plus dexamethasone or belantamab mafodotin are valid.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Observed toxic effects were consistent with those in previous reports.11”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Partly supportedcites [11] 11. Raje N, Berdeja J, Lin Y, et al. Anti- BCMA CAR T-cell therapy bb2121 in re- lapsed or refractory multiple myeloma. N Engl J Med 2019; 380: 1726-37. sourceExperimental — accuracy not yet measured
The Results (Safety; page unavailable) document the observed toxic effects. The Discussion compares them with previous studies, but reports a lower incidence of severe cytokine release syndrome with bb2121 and cautions that cross-study comparisons are complicated. It does not establish that the toxic effects were generally consistent with previous reports. (LLM, conf=0.82)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Duration of undetectable sBCMA correlated with response duration, and clearance of sBCMA at month 2 was associated with longer progression-free survival (Fig. S5E and S5F).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Figure 2 (facing page). Progression-free Survival, Duration of Response, and Overall Survival.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with peak levels higher in patients having cytokine release syndrome of grade 3 or higher (Fig. S6).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a somewhat higher frequency and somewhat greater depth of response were observed at the 450 × 10 6 dose (response in 81% of the pa-tients and complete response or better in 39%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At baseline, 110 of 112 tumor samples (98%) expressed BCMA, with 109 having at least 50% BCMA-positive plasma cells, and all the patients had detectable levels of sBCMA.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Figure 2 (facing page). Progression-free Survival, Duration of Response, and Overall Survival.
Strength:plain· not yet calibratedn = 112Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A response was observed in 73% of the treated patients, and a complete response or better was observed in 33%;”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline cytokine levels were not associated with higher-grade cytokine release syndrome or neurotoxic effects.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with an incidence of response to bridging therapy of 4%”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 12
- It may state two separate claims as one. 32
- The quote only partly states this claim. 1
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In contrast, CD19 epitope loss is reported to be a relatively common escape mechanism after treatment with CD19-directed CAR T-cell therapy, especially in patients with acute leukemia.18,19”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Partly supportedcites [18] 18. Cheng J, Zhao L, Zhang Y, et al. Un- derstanding the mechanisms of resis- tance to CAR T-cell therapy in malignan- cies. Front Oncol 2019; 9: 1237. sourceExperimental — accuracy not yet measured
The Tumor Factors section reports that loss of the targeted CD19 epitope enabled escape after anti-CD19 CAR T-cell therapy in relapsed B-ALL. It also reports that target-antigen-negative relapse accounts for approximately 9–25% of B-ALL relapses, but does not establish that epitope loss specifically is relatively common or more common in acute leukemia than in other malignancies. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [19] 19. Badar T, Shah NN. Chimeric antigen receptor T cell therapy for acute lympho- blastic leukemia. Curr Treat Options On- col 2020; 21: 16. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with persistent grade 3 or 4 neutropenia (52 patients) or thrombocytopenia (62 patients) 1 month after infusion, the median time to recovery to grade 2 or lower was 1.9 months (range, 1.2 to 5.6) and 2.1 months (range, 1.2 to 13.8), respectively”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 52Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimated median progression-free survival was 8.8 months overall (95% CI, 5.6 to 11.6), 12.1 months (95% CI, 8.8 to 12.3) at the 450 × 10 6 dose, and 20.2 months (95% CI, 12.3 to could not be estimated) in patients having a complete or stringent complete response”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 128 treated patients had received a median of 6 previous antimyeloma regimens (range, 3 to 16), and 120 (94%) had received previous autologous hematopoietic stem-cell transplants (Table 1).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Patients
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although high interpatient variability was observed at all doses, upper quartiles of exposure (area under the curve of the transgene level from time of dose to 28 days [AUC 0-28 days ]) were observed more frequently at the 450 × 10 6 dose (Fig. 3B).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among treated patients, 5 were positive for antidrug antibodies before infusion.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline sBCMA levels were elevated in treated patients and de-creased rapidly after infusion in patients who had a response, with nadir values achieved within 3 months (Fig. 3A and Fig. S5B and S5C).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%); no neurotoxic effects higher than grade 3 occurred.”
- Also stated in: § Table 1. (Continued.) · plain
“Investigator-identified neurotoxic effects were reported in 23 patients (18%), of whom 4 (3%) had grade 3 events; no grade 4 or 5 neu-rotoxic effects were observed”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Table 1. (Continued.) · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time to first response was 1.0 month (range, 0.5 to 8.8); the median time to a complete response or better was 2.8 months (range, 1.0 to 11.8).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, neurotoxic effects of any grade were reported in 0 of 4 patients, 12 of 70 patients (17%), and 11 of 54 patients (20%), respectively, with grade 3 events in 0 patients, 1 patient (1%), and 3 patients (6%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 54Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Antidrug antibodies had no effect on the incidence of response or of complete response or better and had no noticeable effect on progression-free survival.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The absence of a detectable effect of antidrug antibodies on efficacy is not due to insufficient statistical power.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimated median overall survival was 19.4 months (95% CI, 18.2 to could not be estimated), with an overall survival of 78% at 12 months (Fig. 2D).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Exposures were higher in patients who had a response than in those who did not (Fig. S5A), and higher exposure was associated with deeper response and longer progression-free survival (Fig. 3C and 3D).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Achievement of undetectable sBCMA levels increased with depth of response (17 of 27 pa-”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe quote only partly states this claim.
- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, cytokine release syndrome of any grade was observed in 2 of 4 patients (50%), 53 of 70 patients (76%), and 52 of 54 patients (96%), respectively, with cytokine release syndrome of grade 3 or higher observed in 0 patients, 4 patients (6%), and 3 patients (6%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimate for median duration of response was 10.7 months (95% CI, 9.0 to 11.3) overall and 11.3 months (95% CI, 10.3 to 11.4) at the 450 × 10 6 dose”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher.”
- Also stated in: § Table 1. (Continued.) · plain
“Cytokine release syndrome occurred in 107 patients (84%) and was mostly of grade 1 or 2 (Table 2 and Table S10).Five patients (4%) had grade 3 cytokine release syndrome, 1 (<1%) had grade 4, and 1 (<1%) had grade 5 (300 × 10 6 dose level).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Table 1. (Continued.) · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 88 patients (69%) and were of grade 3 or 4 in 28 (22%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 88Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“including many with a high tumor burden, high-risk cytogenetic abnormalities, and extramedullary disease.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Common toxic effects among the 128 treated patients included neutropenia in 117 patients (91%), anemia in 89 (70%), and thrombocytopenia in 81 (63%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After disease progression, 28 patients were retreated with ide-cel (Table S4).Six patients (21%) had a second response, with durations of response ranging from 1.9 to 6.8 months; all the patients who had a response were retreated at a dose higher than their initial dose.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most grade 3 or 4 events were hematologic toxic effects, including neutropenia in 114 patients (89%), anemia in 77 (60%), and thrombocytopenia in 67 (52%), and were at least partially related to the lymphodepleting chemotherapy administered before ide-cel infusion.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 114Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 44 treated patients (34%) died during the study, with most deaths (27) attributed by the investigator to complications of myeloma progression (Table S12).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 44Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Levels of proinflammatory markers, including cytokines, ferritin, and C-reactive protein, increased early after ide-cel infusion and decreased by month 1”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The response duration increased with the depth of response; the median response duration was 4.5 months (95% CI, 2.9 to 6.7), 10.4 months (95% CI, 5.1 to 11.3), and 19.0 months (95% CI, 11.3 to could not be estimated) in patients having a best response of partial response (27 patients), very good partial response (25 patients), and complete or stringent complete response (42 patients),”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the target doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, a response was observed in 2 of 4 patients (50%), in 48 of 70 patients (69%), and in 44 of 54 patients (81%), respectively, and a complete response or better was observed in 1 of 4 patients (25%), in 20 of 70 patients (29%), and in 21 of 54 patients (39%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients (4%) died after 6 months from unrelated adverse events, and an additional 8 patients (6%) died after disease progression.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 5Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Minimal residual disease (MRD)-negative status (<10 -5 nucleated cells) was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better.”
- Also stated in: § Efficacy · plain
“Of the 42 patients with a complete or stringent complete response, 33 (79%) also had MRDnegative status at a sensitivity level of 10 -5 , corresponding to 26% (95% CI, 19 to 34) of the treated population; the remaining 9 patients (21%) could not be evaluated for MRD”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 33Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Efficacy · plain
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“High-grade hematologic toxic effects were common but transient.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The fact that MRDnegative responses occurred in approximately a quarter of the patients highlights the depth of response induced by ide-cel.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: MRD negativity at a sensitivity of 10^-5 is a valid measure of depth of response and clinical benefit.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol was approved by local or independent institutional review boards or ethics committees at participating sites.All the patients provided written informed consent.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nearly all tumors expressed BCMA, a finding that supports the use of ide-cel in relapsed and refractory myeloma without restriction based on tumor BCMA expression.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: BCMA expression is required for ide-cel efficacy, so lack of tumor BCMA expression would limit its use.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary efficacy analysis was performed in the population of patients treated with ide-cel (128 patients).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Between December 13, 2017, and November 13, 2018, a total of 140 patients were enrolled and underwent leukapheresis, of whom 128 received ide-cel infusions.Twelve patients discontinued the study before ide-cel infusion (including 1 patient who discontinued after unsuccessful manufacture of the CAR T-cell product)”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Patients
Strength:plain· not yet calibratedn = 140Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was designed by the authors in conjunction with the sponsors and conducted in accordance with the International Council for Harmonisation guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sample size for the primary end point (overall response) was based on a onesample binomial test with normal approximation, under the assumption of 15% dropout between the time of enrollment and ide-cel treatment.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Statistical tests were not performed on subgroup analyses.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary end point was an overall response (partial response or better), defined according to IMWG Uniform Response Criteria for Multiple Myeloma 12 as assessed by an independent review committee.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“MRD negativity was evaluated in bone marrow aspirates by next-generation sequencing (clonoSEQ, Adaptive Biotechnologies) with a minimum cutoff of 10 -5 nucleated cells.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The actual doses delivered were within 20% of the target doses.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Design and Patients
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.Cytokine release syndrome was graded according to published criteria (Table S2).14”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Soluble BCMA is a serum-based universal marker of myeloma burden.
“Soluble BCMA was assessed as a serum-based universal marker of myeloma burden.”
The paper relies on this without support.
Cross-trial comparisons of progression-free survival between the KarMMa study and trials of selinexor plus dexamethasone or belantamab mafodotin are valid.
“These efficacy results compare favorably with results in similarly heavily pretreated patients with relapsed or refractory myeloma treated with two recently approved regimens, selinexor plus dexamethasone and belantamab mafodotin (median progression-free survival, 3.7 months and 2.9 months, respectively).5,17”
The paper relies on this without support.
MRD negativity at a sensitivity of 10^-5 is a valid measure of depth of response and clinical benefit.
“The fact that MRDnegative responses occurred in approximately a quarter of the patients highlights the depth of response induced by ide-cel.”
The paper relies on this without support.
BCMA expression is required for ide-cel efficacy, so lack of tumor BCMA expression would limit its use.
“Nearly all tumors expressed BCMA, a finding that supports the use of ide-cel in relapsed and refractory myeloma without restriction based on tumor BCMA expression.”
The paper relies on this without support.
The absence of a detectable effect of antidrug antibodies on efficacy is not due to insufficient statistical power.
“Antidrug antibodies had no effect on the incidence of response or of complete response or better and had no noticeable effect on progression-free survival.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are newly approved CAR-T products targeting BCMA that are active in relapsed refractory myeloma.89,90”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Safety of ide-cel remained consistent with the IA, with no parkinsonism, Guillain-Barré syndrome, or SPMs of T-cell origin reported. 13”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Common side effects such as CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were mostly low grade, indicating manageable toxicity.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The median duration of response (mDOR) was 11 months in patients achieving CR and 19 months in those achieving stringent complete response (sCR).”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Median DOR and PFS were 10.7 months and 8.8 months, respectively, for ide-cel, and were both not reached for cilta-cel5,6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although follow-up is still ongoing, among patients with ≥CR, DOR and PFS at 15 months with elranatamab were comparable to those observed with other BCMA-targeted T-cell-redirecting therapies, suggesting similar outcomes once a deep response is achieved5,24,25.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High response rates have been reported with the BCMA chimeric antigen receptor (CAR) T-cell therapies, ide-cel and cilta-cel, with responses reported in 73% and 97% of treated patients, respectively.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among 128 patients with relapsed refractory myeloma treated on a phase II trial, ide-cel was associated with a response rate of 73%.89 Thirty three percent of patients had a complete response or better. The median PFS was 8.8 months.”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome was seen in 84%, and 5% were grade 3 or higher. Neurotoxicity was seen in 18%, and was grade 3 in 3%.”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Chimeric antigen receptor (CAR) T-cell therapy has shown promising ef fi cacy in patients with TCE R/RMM. 13-21”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“In the KarMMa study involving 128 patients with RRMM, the overall response rate (ORR) to a single infusion of Abecma was 73%, with a complete response (CR) rate of 33%.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
The cited source says what the claim attributes to it.
In the citing paper
“Abecma has demonstrated the ability to induce rapid, deep, and long-lasting remissions with just one infusion, providing a new and effective personalized therapy option for MM patients [227, 243, 258, 259].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Recently approved therapies such as selinexor, 9 belantamab mafodotin, 10 idecabtagene vicleucel, 11 and ciltacabtagene autoleucel 12 have had clinical benefit in patients with relapsed or refractory multiple myeloma.”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [11]
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationOral selinexor-dexamethasone for triple-class refractory multiple myeloma.
Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903455 · Cited by 666
Self-citationOutcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Friedman, K. M., Garrett, T. E., Evans, J. W., Horton, H. M., Latimer, H. J., Seidel, S. L., Horvath, C. J., & Morgan, R. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.001 · Cited by 205
Treatment of relapsed and refractory multiple myeloma
Sonneveld, P., & Broijl, A. (2016) · Haematologica · doi:10.3324/haematol.2015.129189 · Cited by 181
CAR T-cell therapy in hematologic malignancies: a voyage in progress.
Holstein, S. A., & Lunning, M. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1674 · Cited by 172
Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., & Zhou, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01237 · Cited by 153
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,601–1,700 of 2,535
Ho, P. J., Quach, H., Sidiqi, M. H., Lee, C. H., Butler, J., Spencer, A. G., Micklethwaite, K. P., Li, J., Cusson, E., Bagnall, R., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1535869 · Cited by 3
Allogeneic chimeric antigen receptors (CARs) as an “off-the-shelf” therapy in multiple myeloma
Carlson, S. G., Lin, T. L., & Larson, S. M. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2461987 · Cited by 4
“Given this wait time, in both CARTITUDE-4 and KarMMa-1, majority of patients required bridging therapy to combat disease progression during cell manufacturing [14,17].”
InfluentialChallenges in Multiple Myeloma Therapy in Older and Frail Patients
Aureli, A., Marziani, B., Sconocchia, T., Pasqualone, G., Franceschini, L., Spagnoli, G. C., Venditti, A., & Sconocchia, G. (2025) · Cancers · doi:10.3390/cancers17060944 · Cited by 3
“Accordingly, the oldest patients included in two important CAR-T phase 2 clinical trials, namely, KarMMa [58] and CARTITUDE-1 [59], were 78 and 70 years old, respectively.”
Richter, J. R., Nooka, A. K., Rodríguez‐Otero, P., Schjesvold, F. H., Katodritou, E., Combe, E., Scott, M., Cooper, L., Sly, I., Ballew, N., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.27661 · Cited by 3
Apheresis collection parameters for approved CAR T‐cell products need to be standardized
Mamo, T., Meulners, L., Johnson, A. D., et al. (2025) · Transfusion · doi:10.1111/trf.18216 · Cited by 3
Watson, E. C. R., Djebbari, F., Panitsas, F. P., Vallance, G. D., Asher, S., Saeed, M., Walker, M., Powell, M., Rampotas, A., Leary, H., et al. (2025) · eJHaem · doi:10.1002/jha2.70039 · Cited by 2
Ameen, D., Amini‐Salehi, E., Nayak, S. S., et al. (2025) · Medicine · doi:10.1097/md.0000000000042314 · Cited by 3
“[53] 57] The “combination therapy” cluster was identified as the second most crucial, focusing on research into various therapeutic combinations.”
Current and Future Directions of Immunotherapies in Multiple Myeloma
Biltibo, E. A., Surapaneni, M., Hadidi, S. A., Suvannasankha, A., & Jayani, R. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473316 · Cited by 4
Challenges facing CAR T-cell immunotherapy in multiple myeloma
Ouyang, W., & Mi, J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104803 · Cited by 3
Li, W., Xiao, X., Jing, X., Zheng, Y., Sun, X., Bai, W., Li, M., Luo, M., & Xiao, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1607778 · Cited by 4
“Anti-BCMA CAR-T cell therapy became the fi rst cellular immunotherapy approved by the U.S. Food and Drug Administration (FDA) in 2021 for the treatment of multiple myeloma, achieving unprecedented clinical ef fi cacy (19, 20).”
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma
Kourtesakis, A., Bailey, E., Chow, H. N. H., Rohdjeß, H., Mussnig, N., Agardy, D. A., Hoffmann, D. C. F., Chih, Y., Will, R. D., Kaulen, L. D., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2518631 · Cited by 5
Cheema, M. A., Syed, S., & GHUMAN, Z. (2025) · Archive of Clinical Cases · doi:10.22551/2025.47.1202.10320 · Cited by 3
“While CRS episodes are frequently mild, more severe forms — and even neurotoxicity similar to that seen in CAR-T therapy — have been reported [10,11].”
Ahn, S., Vo, M.-C., Nguyen, V., Tran, V.-D.-H., Duc, T. N., Kim, M., Song, G., Ahn, J., Yang, D., Kim, H., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102475 · Cited by 3
“Even the most advanced CAR-T products, such as idecabtagene vicleucel, have shown a median progression-free survival of only 8.8 months in relapsed/refractory multiple myeloma patients [30,37].”
InfluentialSi, C., Li, Y., Wang, Y., Gao, J., & Ma, X. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167890 · Cited by 3
“Clinically approved CAR-T cell therapies have already demonstrated significant efficacy in the treatment of specific malignancies, including B-cell leukemia [8,9].”
Hao, Y., Wang, Z., Zhang, L., Bai, Y., Yuan, X., Yang, J., Jiang, L., Niu, J., Cheng, W. N., Li, W., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1650568 · Cited by 5
“This approach has demonstrated remarkable ef fi cacy, with reported overall response rate (ORR) ranging from 80% to 100% across clinical trials and real-world evidence (6, 7).”
Santos, J. V. D., Melnekoff, D., Aleman, A., Mouhieddine, T. H., de Oca, R. M., Wang, F., Rajeeve, S., Bhalla, S., Oekelen, O. V., Upadhyaya, B., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025018078 · Cited by 4
Self-citationMulti-hit TP53 confers the poorest survival in multiple myeloma in the era of novel therapies
Nesnadna, R., Petráčková, A., Minařík, J., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01392-2 · Cited by 3
Tagging and Capturing of Lentiviral Vectors Using Short RNAs
Panigaj, M., Marino, M. P., & Reiser, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910263 · Cited by 3
“Four LV vector-based gene therapy products have received regulatory approval, including Kymriah (tisagenlecleucel) for the treatment of relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) [4], Zynteglo (betibeglogene autotemcel) for the treatment of transfusion-dependent beta-thalassemia [5], Breyanzi (lis…”
BackgroundBridging Chemotherapy: Multiple Myeloma
Manier, S., Jurczyszyn, A. J., & Vesole, D. H. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0_24 · Cited by 3
Watson, E., Djebbari, F., Rampotas, A., & Ramasamy, K. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2084068 · Cited by 3
“with CNS involvement of their disease, and none of ide-cel, cilta-cel, teclistamab or belantamab were tested in patients with plasma cell leukemia [26,36,60,63].”
BackgroundInfluential[The Chinese consensus for the CAR-T cell therapy in multiple myeloma (2022 version)].
(2022) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2022.04.001 · Cited by 3
“[12]Munshi NC, Anderson LD Jr, Shah N, et al.”
BackgroundHarnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm
Keller, A. L., Sherbenou, D. W., Forsberg, P. A., & Mark, T. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.925818 · Cited by 3
“The CD28 CAR T products axicabtagene ciloleucel and brexucabtagene autoleucel (used for non-Hodgkin lymphomas) had neurotoxicity rates of approximately 65%, compared to approximately 20% for the 41BB CAR T products idecabtagene and ciltacabtagene (93, 110, 114, 115).”
BackgroundInfluentialLi, C., Liu, J., Deng, J., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18500 · Cited by 3
Whole-process management of complications during CAR-T therapy
Li, Y., & Mei, H. (2022) · Hematology and Oncology Discovery · doi:10.15212/hod-2022-0005 · Cited by 4
“Ide-cel [96] Multiple myeloma 128 91% 89% 63% 52% 70% 60%”
Antibody Drug Conjugates in Multiple Myeloma
Ferreri, C. J., & Lee, H. C. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000628 · Cited by 4
CAR-T-Zell-basierte Immuntherapien in der Hämatoonkologie
Steinhardt, M., Reinhardt, L., Luu, M., Danhof, S., & Hudecek, M. (2023) · Die Onkologie · doi:10.1007/s00761-022-01299-1 · Cited by 3
van Not, O. J., van den Eertwegh, A. J. M., Haanen, J. B. A. G., van Rijn, R. S., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers‐Sonderen, M. J., van Eijs, M. J. M., de Groot, J. B., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.009 · Cited by 3
Expansion of mixed immune cells using CD3/CD161 co-stimulation for the treatment of cancer
Tsumura, R., Haruta, M., Kuwano, M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-33987-2 · Cited by 3
Pitfalls in patenting academic CAR-T cells therapy
Constantinescu, C. S., Constantinescu, R., Bergþorsson, J. Þ., et al. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2220883 · Cited by 3
“Idecabtagene vicleucel [13] and lisocabtagene maraleucel [8] are two newer CAR-T cell therapy approved in 2021, respec-”
BackgroundArcila, M. E., Patel, U., Boroujeni, A. M., Yao, J., Chan, R., Chan, J., Rijo, I., Yu, W., Chaves, N., Patel, H., et al. (2023) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.06.002 · Cited by 3
Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma
Hamilton, M. P., & Miklos, D. B. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.05.007 · Cited by 3
Multiple Myeloma: Current Clinical Landscape and Compounding Costs
Beck, K., Sandahl, T. B., Ailawadhi, S., Khera, N., & Jensen, C. J. (2023) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-023-00705-8 · Cited by 3
The Promise of Immunotherapeutics and Vaccines in the Treatment of Cancer
Gaur, A., & Chirmule, N. B. (2023) · Springer eBooks · doi:10.1007/978-981-99-2196-6_62-1 · Cited by 3
Einloth, K. R., Gayfield, S., McMaster, T., Didier, A. J., Dworkin, L. D., & Creeden, J. F. (2023) · Bioimpacts · doi:10.34172/bi.2023.27521 · Cited by 3
Gómez-Lumbreras, A., Mercadal, S., Zapata, L. V., Malone, D. C., & Couriel, D. R. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2254430 · Cited by 3
CAR-T Therapy of Multiple Myeloma, Based on the Congresses ASH-2021 and ASCO-2022
Семочкин, С. В. (2023) · Clinical oncohematology · doi:10.21320/2500-2139-2023-16-1-1-13 · Cited by 4
Popat, R., Lonial, S., Voorhees, P. M., Esposti, S. D., Gorsh, B., Gupta, I. V., Opalińska, J., Sapra, S. J., Piontek, T., He, Z., et al. (2023) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2023.14.6.4 · Cited by 3
“The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30) is a widely used pan-oncology PRO instrument to assess disease and treatment-related symptoms, HRQOL, and functioning (ability to perform activities of daily life; Fayers et al., 2002), and the EORTC QL…”
InfluentialSelf-citationGarrido‐Alejos, G., Saborit-Canals, G., Guarga, L., et al. (2023) · Cancers · doi:10.3390/cancers15225338 · Cited by 3
Self-citationCasey, M., Lee, C., Hoyte, S. M., Johnston, R. L., Kwok, W. Y., Law, S. C., Gandhi, M. K., Harrison, S. J., & Nakamura, K. (2024) · Haematologica · doi:10.3324/haematol.2023.284435 · Cited by 4
SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program
Voorhees, T. J., Bezerra, E. D., Denlinger, N., Jaglowski, S. M., & Lima, M. J. G. D. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.03.007 · Cited by 3
Adoptive Immune Effector Cell Therapies in Cancer and Solid Organ Transplantation: A Review
Schreiber, B., Tripathi, S., Nikiforow, S., & Chandraker, A. K. (2024) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2024.151498 · Cited by 3
Mellatyar, H., Sattari, S., Asl, A. N., & Akbarzadeh, A. (2024) · BioNanoScience · doi:10.1007/s12668-024-01389-x · Cited by 2
“2) [8–10].”
Hashmi, H., Kumar, A., Kharfan-Dabaja, M., Munshi, P., Inamoto, Y., DeFilipp, Z. M., Dholaria, B. R., Jain, T., Perales, M.-A., Carpenter, P., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.04.007 · Cited by 3
Al-Janabi, I. I. (2024) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v6i2.726 · Cited by 3
Updates to the Management of Multiple Myeloma
Callander, N. S., & Kumar, S. K. (2024) · The Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.5004 · Cited by 5
Advancement in “Off-the-Shelf” CAR T-Cell Therapy for Cancer Immunotherapy
Sheykhhasan, M., La’ah, A. S., Ahmadieh-Yazdi, A., Yang, P., Tanzadehpanah, H., Mahaki, H., Manoochehri, H., Poondla, N., Kalhor, N., & Al-Musawi, S. (2024) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-3976-3.ch002 · Cited by 5
Akhtar, O. S., Szabó, A., Bhatlapenumarthi, V., Forsberg, M., Balev, M., Patwari, A., Cheruvalath, H., Bhutani, D., Thanendrarajan, S., Dhakal, B., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19700 · Cited by 4
“4,5 In comparison, patients receiving bsAb are at increased risk for infections and infection-related mortality.”
Self-citationA phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma
Goldsmith, S., Slade, M. J., Fiala, M., Harding, M., Crees, Z., Schroeder, M. A., Stockerl-Goldstein, K., & Vij, R. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05975-7 · Cited by 4
McCurdy, A. B. R., Reece, D. E., Louzada, M., White, D. J., Parkin, S., Chu, M. P., Kotb, R. R., Mian, H. S., Othman, I., Su, J., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01135-2 · Cited by 4
Self-citationEngaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma
Saied, G., & Halford, Z. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241281742 · Cited by 3
Lancman, G., Song, K., White, D., Crosbie, T., Sharif, I., Emond, M., Raza, M. S., Elias, M., Kaedbey, R., & Chu, M. P. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1446995 · Cited by 3
Advances in CD19-targeting CAR-T cell therapies for multiple myeloma
Steinhardt, M., Einsele, H., & Waldschmidt, J. M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2443093 · Cited by 3
“B-cell maturation antigen (BCMA) has become the lead target antigen for CAR-T cell therapies in MM, and idecabtagene vicleu-cel (ide-cel) [4,5] and ciltacabtagene autoleucel (cilta-cel) [6,7] are now established as therapies with unprecedented response rates in triple-class refractory patients.”
Self-citationGrunblatt, E., Meng, Z., Baldridge, A. S., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2448713 · Cited by 3
Maurer, K., & Jacobson, C. (2025) · Leukemia and Lymphoma · doi:10.1080/10428194.2025.2460043 · Cited by 4
“…outcomes for patients with B cell malignancies. in less than a decade since the first FDA approval of a cAR-t cell therapy, a total of six cAR-t products have now received approvals for B-cell non-Hodgkinlymphomas (B-NHl), B-acute lymphoblastic leukemia (B-All) and multiple myeloma (MM) [1–6].”
Robat-Jazi, B., Mahalleh, M., Dashti, M., Nejati, N., Ahmadpour, M., Alinejad, E., Mohammadi, S., Lorestani, P., Hamidieh, A. A., Habibi, M. A., et al. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206350342241224073809 · Cited by 4
MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma
Zhang, F., Du, H., Liu, K., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06365-x · Cited by 3
“Among other ACT strategies, chimeric antigen receptor-T (CAR-T) cell therapy has been proven effective for hematologic malignancies and certain types of solid tumors [13–17], raising an exciting possibility that mucosal melanoma can become curable towards CAR-T cells.”
Zhang, Z.-P., Zheng, J.-P., Liang, Y., Wu, Q.-M., Ding, C., Ma, L., & Su, L. (2025) · BMC Cancer · doi:10.1186/s12885-025-14227-4 · Cited by 3
Justiz-Vaillant, A. A., Soodeen, S., Gopaul, D., Arozarena-Fundora, R., & Akpaka, P. E. (2026) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2026.1931159 · Cited by 3
“Advances in receptor engineering and manufacturing continue to improve treatment efficacy across haematological malignancies (Schuster et al., 2019; Munshi et al., 2021).”
InfluentialHolstein, S. A., Bahlis, N. J., Bergsagel, P. L., Bhutani, M., Bolli, N., Brownstein, C. M., Démolis, P., Foureau, D., Gay, F., Ghobrial, I. M., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.05.027 · Cited by 3
Self-citationNew indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
Iqbal, M., Savani, B. N., & Hamadani, M. (2021) · eJHaem · doi:10.1002/jha2.323 · Cited by 2
Progress on CAR-T cell therapy for hematological malignancies
Hu, K., Huang, Y., Hu, Y., & Huang, H. (2022) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2022-0055 · Cited by 3
Bertuglia, G., Cani, L., Larocca, A., Gay, F., & D’Agostino, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415879 · Cited by 3
“Immunotherapies based on chimeric antigen receptor (CAR) T cells, which are T cells engineered with a particular T-cell receptor, showed an impressive overall response rate (ORR) in several clinical trials [157–159].”
BackgroundCancanelli, L., Rivano, M., Spazio, L. D., Chiumente, M., Mengato, D., & Messori, A. (2023) · Hematology Reports · doi:10.3390/hematolrep15010006 · Cited by 3
“KarMMa Munshi 2021 [8] Patients with disease after at least three previous regiments, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody were enrolled idecabtagene vicleucel 128 101”
MethodCroizier, C., & de Wyngaert, Z. V. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.10.007 · Cited by 3
Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy
Davis, J. A., Gaffney, K. J., McGann, M., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.09.005 · Cited by 3
CAR-T cell therapy in myeloma: hopes and hurdles
Harousseau, J. L. (2023) · Blood Science · doi:10.1097/bs9.0000000000000148 · Cited by 3
GPRC5D: The Next Frontier for Immunotherapy in Multiple Myeloma
Bhutani, M., & Usmani, S. (2023) · The Hematologist · doi:10.1182/hem.v20.1.202314 · Cited by 3
CAR T-cell therapy for triple-class exposed relapsed/refractory multiple myeloma
Cavo, M. (2023) · Haematologica · doi:10.3324/haematol.2022.282587 · Cited by 3
Self-citationSpencer, A. G., Kalff, A., Shortt, J., Quach, H., Wallington-Beddoe, C. T., Reynolds, J., Walker, P., Harrison, S. J., Dunn, R. D., & Wellard, C. J. (2023) · British Journal of Haematology · doi:10.1111/bjh.18955 · Cited by 3
Idecabtagene vicleucel: questions regarding the appropriate role and cost
Powell, K., Russler‐Germain, D. A., & Prasad, V. K. (2021) · British Journal of Haematology · doi:10.1111/bjh.17784 · Cited by 3
“In the KarMMa trial, grade 1 and 2 cytokine release syndrome (CRS), the most prominent toxicity of CAR-0T therapies, occurred in 107 patients (84%), with five patients (4%) and one patient (<1%) experiencing grade 3 and 4 CRS respectively.(3) Ide-cel incorporates a 4-1BB costimulatory domain, which tends to have CRS o…”
BackgroundMethodMacMullan, M. A., Dunn, Z. S., Qu, Y., Wang, P., & Graham, N. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.24.481820 · Cited by 4
Editorial: T-cell directed therapies in multiple myeloma
Richter, J. R., Anderson, L. D., Ramasamy, K., & Rossi, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1206475 · Cited by 3
Self-citationCalibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell LymphomaPreprint
Park, J. H., Palomba, M. L., Perica, K., Devlin, S. M., Shah, G. L., Dahi, P. B., Lin, R. J., Salles, G., Scordo, M., Nath, K., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4619285/v1 · Cited by 3
Rade, M., Fandrei, D., Kreuz, M., Seiffert, S., Wiemers, T. C., Born, P., Fischer, L., Weidner, H., Hofbauer, L. C., Baber, R., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6165798/v1 · Cited by 3
CAR-T-Zellen: Praktische Aspekte der Anwendung einer innovativen Zelltherapie
Bücklein, V., Blumenberg, V., & Subklewe, M. S. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1303-8708 · Cited by 2
“[16] Munshi NC, Anderson LD, Shah N et al.”
BackgroundNew Enhancing Oncology Model builds on knowledge from the OCM
Staggs, S. (2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.89229 · Cited by 2
CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey
Hakan, G., Engin, K., Elifcan, K. A., Haluk, D., Mehmet, T., Suman, K., & Maxwell, K. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1413825 · Cited by 3
“The safety profile of ide-cel was consistent with what was found in previous research (4, 14).”
BackgroundResultHonaker, Y., Gruber, D., Jacobs, C., Cheng, R. Y.-H., Patel, S., Galvan, C. Z., Khan, I., Zhou, K., Sommer, K., Astrakhan, A., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.018 · Cited by 2
Langa, P., Sharma, K., Sellers, D., et al. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2024.12.009 · Cited by 2
Tumor-Infiltrating Lymphocytes, CAR-, and T-Cell Receptor-Modified T Cells in Solid Cancer Oncology
Echchannaoui, H., Legscha, K. J., & Theobald, M. (2025) · Oncology Research and Treatment · doi:10.1159/000543998 · Cited by 2
Karp, S., Trautmann‐Grill, K., Warncke, P., Zolnowski, D., Röllig, C., Pannach, M., Zinn, J., Kroschinsky, F., Morgner, A., Bonin, M. V., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06262-9 · Cited by 2
“…directed against B-cell matura - tion antigen (BCMA) or GPRC5D on myeloma cells and CD3 on T lymphocytes [12–14], as well as anti-BCMA chimeric antigen receptor (CAR) T cell therapies [15] and antibody-drug conjugates (ADC) [16] have been developed in rapid succession for the treatment of RRMM.”
Zhou, L., Feng, Y., Hong, R., Wei, G., Zhang, M., Chang, A. H., Huang, H., & Hu, Y. (2025) · Science China Life Sciences · doi:10.1007/s11427-024-2783-2 · Cited by 2
“However, evaluation of more patients with lymphoma and multiple myeloma undergoing CAR-T cell therapy has shown that such events are uncommon, with the majority of relapsed patients still expressing CD19 or BCMA (Chong et al., 2021; Munshi et al., 2021; Plaks et al., 2021).”
CAR-T for multiple myeloma: practice pearls
O'Leary, D., & Bachanová, V. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02582-6 · Cited by 2
Neurological complications associated with chimeric antigen receptor T cell therapy
Yan, S., Zhou, M., Zhu, X., & Xiao, Y. (2025) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x251332492 · Cited by 4
Marumo, Y., Ri, M., Ebina, T., et al. (2025) · eJHaem · doi:10.1002/jha2.70040 · Cited by 2
“The treatment protocol including LDC, a combination of cyclophosphamide with fludarabine, was in accordance with the KarMMa study [5].”
van Amerongen, R. A., Tuit, S., Remst, D. F. G., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0119 · Cited by 2
Advances in NK cell therapy for multiple myeloma
Liu, N., Zeng, Y., Wang, Y., Wang, C., Li, N., & Xu, J. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101639 · Cited by 2
Neuromodulation by the immune system: implications for brain-directed immunotherapy
Cho, D. H., Huh, J. R., & Choi, G. B. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102568 · Cited by 2
Wang, J., Xie, T., Peng, J., Zhang, Y., & Zhang, H. (2025) · Health Data Science · doi:10.34133/hds.0325 · Cited by 2
Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure
Kort, J., Rivera, A., Senigarapu, S., & Driscoll, J. J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1578529 · Cited by 2
“Many challenges limit the therapeutic ef fi cacy of CAR-T cells in hematological malignancies (86, 87, 96, 136 – 146).”
Rosenberg, M. C., Scarpetti, L., Morgan, G. J., & Davies, F. E. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.013 · Cited by 2
Encinas, C., Blanchard, M. J., Alonso, R., Hernández‐Rivas, J., Tamayo, R. R., Machado-Vílchez, M., Martínez‐López, J., & Mateos, M. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.012 · Cited by 5
Mouhieddine, T. H., Ghobrial, I. M., & Nadeem, O. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101641 · Cited by 3
Bispecific T-cell engager therapy for multiple myeloma
Cirstea, D. D., Puliafito, B. R., Kim, B. E., Lei, M., & Raje, N. S. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101649 · Cited by 2
Self-citationAutomated vertical wheel bioreactor integrated with process analytics for T-cell manufacturing
Wang, B., Kanwar, B., Bowles, A. C., et al. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.08.007 · Cited by 3
Cellular Immunogenicity Assessments in CAR-T Cell Therapies: Current Insights and Future Directions
Masilamani, M., Balasubramanian, N., Mora, J. R., Park, A., & Jawa, V. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01129-3 · Cited by 2
“…cancers consistently demonstrated a low response over time without affecting CAR-T cellular kinetics, persistence or patient outcomes (1, 35, 44–47), questioning the value of such assessments to the overall clinical development of CAR-T therapies; instead it may be justified case by case based…”
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists
Mushtaq, A. H., Cheema, A. Y., Ali, H. M., Shatnawi, Y., Ashruf, O. S., Ahmad, E. N., Lytvynova, O., Munir, M., Asif, M. A., Ahmad, M., et al. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101339 · Cited by 4
Bahlis, N. J., Zonder, J. A., Karlin, L., Plesner, T., París, L., Wróbel, T., Hungria, V., Besemer, B., Crusoé, E., Silkjær, T., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2561117 · Cited by 3
Self-citationEngineering T cells for cancer: The evolution and future of CAR-based therapies
Unni, A., & Shankar, P. R. (2025) · Next research. · doi:10.1016/j.nexres.2025.100892 · Cited by 4
Munárriz, D., Rodríguez-Lobato, L., López-Corral, L., Arnaldos-Pérez, C., Cabañas, V., López-Muñoz, N., Oliver-Cáldes, A., Ponce, J. C., Reguera, J. L., Martin, A., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1654096 · Cited by 2
Metadata
- Authors
- Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H., Weisel, K., Rambaldi, A., Reece, D., Petrocca, F., Massaro, M., Connarn, J. N., Kaiser, S., Patel, P., Huang, L., Campbell, T. B., Hege, K., & San-Miguel, J.
- Affiliations
- Harvard University (US)
- Mayo Clinic (US)
- Hackensack University Medical Center (US)
- From the Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute (N.C.M.), the Veterans Affairs Boston Healthcare System, Harvard Medical School (N.C.M.), and Massachusetts General Hospital (N.R.), Boston, and bluebird bio, Cambridge (F.P., M.M.) — all in Massachusetts; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.); the University of California, San Francisco, San Francisco (N.S.); Icahn School of Medicine at Mount Sinai, New York ...
- ORCID
- Munshi, Nikhil C.
- Anderson, Larry D.
- Shah, Nina
- Madduri, Deepu
- Berdeja, Jesús
- Lonial, Sagar
- Raje, Noopur
- Lin, Yi
- Siegel, David
- Oriol, Albert
- Moreau, Philippe
- Yakoub-Agha, Ibrahim
- Delforge, Michel
- Einsele, Hermann
- Goldschmidt, Hartmut
- Weisel, Katja
- Rambaldi, Alessandro
- Reece, Donna
- Petrocca, Fabio
- Connarn, Jamie N.
- Kaiser, Shari
- Patel, Payal
- Huang, Liping
- Campbell, Timothy B.
- Hege, Kristen
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-25
- Volume
- 384
- Issue
- 8
- Pages
- 705-716
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3133229959
- Semantic Scholar
- fd96e2f87dff7d1153a17b78b56fbbab69cb714e
- Cited by
- 2,560
- References
- 17
- Citations by year
- 2026: 411 · 2025: 486 · 2024: 540 · 2023: 493 · 2022: 436 · 2021: 186
- FWCI
- 150.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- idecabtagene vicleucel, CAR T-cell therapy, relapsed/refractory multiple myeloma, BCMA, minimal residual disease, cytokine release syndrome, neurotoxicity, CAR T cell persistence, progression-free survival, complete response, neutropenia, anemia, thrombocytopenia, chimeric antigen receptor T cells
- MeSH terms
- Receptors, Chimeric Antigen, Progression-Free Survival, Cytokine Release Syndrome, Adult, Aged, Female, Hematologic Diseases, Humans, Male, Middle Aged, Multiple Myeloma, Recurrence, Biomarkers, Immunotherapy, Adoptive, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
